InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (12 ops.)
Discover the complete record of transactions filed by Conroy Kevin T, Chief Executive Officer and Chairman of the Board. Director active across 4 companies, notably Exact Sciences CORP. Cumulatively, 35 disclosures have been recorded. Total volume traded: €16.3m. The latest transaction was filed on 17 May 2022 — Attribution. Regulator: SEC (Form 4). The full history is openly available.
Declarations35 total
08,994 shares0
Common Stock, par value $0.0001
SEC:0000899243-22-018826:0·
€13,54713,043 shares@ €1.038614.8% of flow
Common Stock, par value $0.0001
SEC:0000899243-22-013150:0·
€1m229,757 shares@ €5.17150.0059% mcap6.5% of flow
Common Stock
SEC:0001209191-22-020021:0·
020,575 shares0
Common Stock
SEC:0001209191-22-014952:0·
058,643 shares0
Common Stock
SEC:0001209191-22-013334:0·
010,373 shares0
Common Stock
SEC:0001209191-22-012829:0·
€753,56894,425 shares@ €7.98060.0038% mcap4.1% of flow
Common Stock
SEC:0001209191-22-010395:0·
06,689 shares0
Common Stock
SEC:0001209191-22-005498·
06,689 shares0
Common Stock
SEC:0001209191-22-005498:0·
06,407 shares0
Common Stock
SEC:0001209191-22-003761·
06,407 shares0
Common Stock
SEC:0001209191-22-003761:0·
€13,2456,000 shares@ €2.207534.1% of flow
Common Stock, par value $0.0001
SEC:0000899243-22-000498·
€13,2456,000 shares@ €2.207514.5% of flow
Common Stock, par value $0.0001
SEC:0000899243-22-000498:0·
€1m16,922 shares@ €81.23440.0069% mcap16.8% of flow
Common Stock
SEC:0001209191-21-062738·
€1m16,922 shares@ €81.23440.0069% mcap7.5% of flow
Common Stock
SEC:0001209191-21-062738:0·
€1m17,078 shares@ €80.90220.0069% mcap16.9% of flow
Common Stock
SEC:0001209191-21-059601·
€1m17,078 shares@ €80.90220.0069% mcap7.5% of flow
Common Stock
SEC:0001209191-21-059601:0·
€12,9612,930 shares@ €4.423533.4% of flow
Common Stock, par value $0.0001
SEC:0000899243-21-038633·
€12,9612,930 shares@ €4.423514.2% of flow
Common Stock, par value $0.0001
SEC:0000899243-21-038633:0·
€2m18,978 shares@ €88.18580.0084% mcap20.5% of flow
Common Stock
SEC:0001209191-21-054728·
025,000 shares0
Class A Common Stock
SEC:0001213900-21-046743·
€2m18,978 shares@ €88.18580.0084% mcap9.1% of flow
Common Stock
SEC:0001209191-21-054728:0·
025,000 shares0
Class A Common Stock
SEC:0001213900-21-046743:0·
€2m19,970 shares@ €90.5290.0090% mcap22.1% of flow
Common Stock
SEC:0001209191-21-049629·
€2m19,970 shares@ €90.5290.0090% mcap9.9% of flow
Common Stock
SEC:0001209191-21-049629:0·
25 of 35 declarations
About Conroy Kevin T
Kevin T. Conroy is best known as the Chief Executive Officer and Chairman of the Board of Exact Sciences Corp., where he has served in senior leadership since 2009 and as Chairman since 2014. His career has been built in the molecular diagnostics, healthcare technology, and life sciences sectors, with more than two decades of experience spanning legal, strategic, and executive leadership roles. Prior to Exact Sciences, he served as President and Chief Executive Officer of Third Wave Technologies, and earlier as General Counsel of the same company, giving him deep experience at the intersection of innovation, regulation, and commercialization. He also worked at GE Healthcare as intellectual property counsel, further strengthening his foundation in healthcare technology and corporate strategy. At Exact Sciences, Conroy has been closely associated with the company’s evolution into a leading cancer diagnostics business. His leadership has covered a period of sustained growth, including the development, regulatory approval, and commercialization of diagnostic tests, as well as the buildout of a high-performing organizational culture. His profile reflects a blend of executive leadership, corporate strategy, finance, M&A insight, and governance experience, which is particularly relevant in highly regulated healthcare and biotechnology markets. Beyond Exact Sciences, he has served on the boards of several public or public-market-adjacent life sciences companies, including Adaptive Biotechnologies Corp., Epizyme, Inc., and SomaLogic, Inc. These board roles indicate that he has been valued for strategic oversight and sector expertise across biotech and diagnostics businesses. In those settings, his contributions have generally centered on governance, growth strategy, and helping management teams navigate commercialization and value creation. Overall, Kevin T. Conroy stands out as a seasoned U.S. biotech executive whose career has been defined by building and scaling diagnostics platforms, leading through regulatory and commercial milestones, and supporting innovation-driven healthcare companies.
